110 related articles for article (PubMed ID: 30213299)
21. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Takeuchi S; Yoshimura K; Fujiwara T; Ando M; Shimizu S; Nagase K; Hasegawa Y; Takahashi T; Katakami N; Inoue A; Yano S
J Med Invest; 2017; 64(3.4):321-325. PubMed ID: 28955007
[TBL] [Abstract][Full Text] [Related]
23. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Corrales-Rodriguez L; Martín C; Reguart N; Archila P; Rodríguez J; Cuello M; Ortíz C; Franco S; Rolfo C; Rosell R; on behalf of the CLICaP
Oncotarget; 2016 Sep; 7(42):68933-68942. PubMed ID: 27926478
[TBL] [Abstract][Full Text] [Related]
24. Exploratory cohort study and meta-analysis of
Sun S; Yu H; Wang H; Zhao X; Zhao X; Wu X; Qiao J; Chang J; Wang J
Onco Targets Ther; 2017; 10():1955-1967. PubMed ID: 28435285
[TBL] [Abstract][Full Text] [Related]
25. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
26. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
[TBL] [Abstract][Full Text] [Related]
27. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.
Zou Q; Zhan P; Lv T; Song Y
Transl Lung Cancer Res; 2015 Dec; 4(6):792-6. PubMed ID: 26798589
[TBL] [Abstract][Full Text] [Related]
28. Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Xia J; Bai H; Yan B; Li R; Shao M; Xiong L; Han B
Oncotarget; 2017 Dec; 8(65):108522-108533. PubMed ID: 29312548
[TBL] [Abstract][Full Text] [Related]
29. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.
Zhong J; Li ZX; Zhao J; Duan JC; Bai H; An TT; Yang XD; Wang J
Thorac Cancer; 2014 Nov; 5(6):509-16. PubMed ID: 26767045
[TBL] [Abstract][Full Text] [Related]
30. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Song KA; Niederst MJ; Lochmann TL; Hata AN; Kitai H; Ham J; Floros KV; Hicks MA; Hu H; Mulvey HE; Drier Y; Heisey DAR; Hughes MT; Patel NU; Lockerman EL; Garcia A; Gillepsie S; Archibald HL; Gomez-Caraballo M; Nulton TJ; Windle BE; Piotrowska Z; Sahingur SE; Taylor SM; Dozmorov M; Sequist LV; Bernstein B; Ebi H; Engelman JA; Faber AC
Clin Cancer Res; 2018 Jan; 24(1):197-208. PubMed ID: 29051323
[No Abstract] [Full Text] [Related]
31. Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism.
Liu SY; Zhou JY; Li WF; Sun H; Zhang YC; Yan HH; Chen ZH; Chen CX; Ye JY; Yang JJ; Zhou Q; Zhang XC; Wu YL
Clin Transl Med; 2020 Jan; 10(1):337-345. PubMed ID: 32508032
[TBL] [Abstract][Full Text] [Related]
32. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Takeuchi S; Yano S
Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
[TBL] [Abstract][Full Text] [Related]
34. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
Wu DW; Chen CY; Chu CL; Lee H
Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
[TBL] [Abstract][Full Text] [Related]
35. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract][Full Text] [Related]
36. Real-time PCR assay with high resolution melting for EGFR and BIM mutation of lung cancer.
Xia JJ; Zhao SF; Xiong LW; Chu TQ; Bai H; Yan B; Zhong RB; Shao MH; Han BH
Eur Rev Med Pharmacol Sci; 2016 Jul; 20(13):2805-11. PubMed ID: 27424979
[TBL] [Abstract][Full Text] [Related]
37. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
[TBL] [Abstract][Full Text] [Related]
38. The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
Rauzan M; Chuah CT; Ko TK; Ong ST
PLoS One; 2017; 12(3):e0174107. PubMed ID: 28301600
[TBL] [Abstract][Full Text] [Related]
39. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
40. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
